Now showing items 1-3 of 3
Renal safety of lithium in HIV-infected patients established on tenofovir disoproxil fumarate containing antiretroviral therapy : analysis from a randomized placebo-controlled trial
(BioMed Central, 2017-02-04)
Background: The prevalence of bipolar disorder in HIV-infected patients is higher than the general population. Lithium is the most effective mood stabiliser, while tenofovir disoproxil fumarate (TDF) is frequently used ...
Simulating therapeutic drug monitoring results for dose individualisation to maintain investigator blinding in a randomised controlled trial
(BioMed Central, 2017-06-07)
Background: Therapeutic drug monitoring (TDM) is essential practice when dosing drugs with a narrow therapeutic index in order to achieve a plasma drug concentration within a narrow target range above the efficacy concentration ...
Moderate to severe HIV-associated neurocognitive impairment : a randomized placebo-controlled trial of lithium
(Wolters Kluwer Health, 2016-11)
Background: HIV-associated neurocognitive disorder (HAND) remains highly prevalent despite effective anti-retroviral therapy (ART). A number of adjunctive pharmacotherapies for HAND have been studied with disappointing ...